Financial valuations in the biotechnology sector are reaching new heights as the first wave of MSC-based therapies achieves commercial success. In 2026, the industry is no longer viewed as a speculative venture but as a cornerstone of the modern pharmaceutical portfolio. Large-cap pharmaceutical companies are aggressively acquiring smaller biotech firms to secure intellectual property and...